To date, there has not been an evaluation of antipsychotic prescription practices specific to the Association of Southeast Asian Nations (ASEAN) region. This study examined antipsychotic prescription for schizophrenia patients in ASEAN countries based on Research on Asian Psychotropic Prescription (REAP) survey.
Methods
This study used data from the fourth REAP antipsychotic survey (REAP-AP4), conducted between March and May 2016 using standardized procedures. In total, 1817 adult schizophrenia patients from six ASEAN countries were analysed.
Results
Prescription formulation was significantly associated with illness duration (G (24) = 150.595, p < .001) and prescribing country (G (20) = 571.423, p < .001). Oral antipsychotic monotherapy was the most common prescription across all illness durations, with a decreasing trend from 3–6 months to 10–20 years. Oral antipsychotic monotherapy was also the most commonly used prescription in almost all countries. The frequency of long-acting injection (LAI)-oral combination antipsychotic prescription increased with the patient’s illness duration and is more commonly prescribed in Malaysia, Singapore, and Thailand.
Conclusion
LAI-oral combination antipsychotics were prescribed more frequently within patients with longer duration of illness in more developed countries. Antipsychotic monotherapy and oral antipsychotic prescriptions were prevalent across all illness durations and in most ASEAN countries.
SultanaJHurtadoIBejarano-QuisoboniD, et al.Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Eur J Clin Pharmacol2019; 75: 1005–1015.
2.
DongMZengLNZhangQ, et al.Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 research on Asian psychotropic prescription patterns (REAP) survey. Asian J Psychiatr2019; 45: 74–80.
3.
YangSChenLNajoanE, et al.Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatr Clin Neurosci2018; 72: 572–579.
4.
ChongMYTanCHShinfukuN, et al.Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: comparison of REAP-2001 and REAP-2004 studies. Asia Pac Psychiatry2010; 2: 77–84.
5.
XiangYTUngvariGSCorrellCU, et al.Trends in the access to and the use of antipsychotic medications and psychotropic co-Treatments in Asian patients with schizophrenia. Epidemiol Psychiatr Sci2016; 25: 9–17.
6.
UNDP. Human development report 2020, the next frontier: human development and the anthropocene. New York, UNDP, 2020.
7.
ChongMYTanCHFujiiS, et al.Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatr Clin Neurosci2004; 58: 61–67.
8.
BosanacPCastleDJ. Why are long-acting injectable antipsychotics still underused?BJPsych Adv2015; 21: 98–105.
9.
TakeuchiHSuzukiTUchidaH, et al.Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res2012; 134: 219–225.
10.
SajatovicMRossRLegacySN, et al.Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. Neuropsychiatric Dis Treat2018; 14: 1475–1492.
11.
DruaisSDoutriauxACognetM, et al.Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics2016; 34: 363–391.
12.
Van MinhHSuyin PocockNChaiyakunaprukN, et al.Progress toward universal health coverage in ASEAN. Glob Health Action; 7: 1-12. DOI: 10.3402/gha.v7.25856.
13.
MyintCPavlovaMGrootW. Health insurance in Myanmar: knowledge, perceptions, and preferences of Social Security Scheme members and general adult population. Int J Health Plann Manag2019; 34: 346–369.
14.
GonzálezGPMoscosoNSLagoFP. A review of clinical and economic evaluations applied to psychotropic therapies used in the treatment of schizophrenia in Argentina. Pharmacoecon Open2018; 2: 233–239.
15.
CorriganPWWatsonAC. The stigma of psychiatric disorders and the gender, ethnicity, and education of the perceiver. Community Ment Health J2007; 43: 439–458.
16.
KudvaKGEl HayekSGuptaAK, et al.Stigma in mental illness: perspective from eight Asian nations. Asia Pac Psychiatry2020; 12: e12380.
17.
HartiniNFardanaNAArianaAD, et al.Stigma toward people with mental health problems in Indonesia. Psychol Res Behav Manag2018; 11: 535–541.
18.
LoraAKohnRLevavI, et al.Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low-and middle-income countries. Bull World Health Organ2012; 90: 47–54.
19.
DemyttenaereKBruffaertsRPosada-VillaJ, et al.Prevalence, severity, and unmet need for treatment of mental disorders in the world health organization world mental health surveys. J Am Med Assoc2004; 291: 2581–2590.
20.
NgCH. Mental health and integration in Asia pacific. BJPsych Int2018; 15: 76–79.
21.
OwenPR. Portrayals of schizophrenia by entertainment media: a content analysis of contemporary movies. Psychiatr Serv2012; 63: 655–659.
22.
IyerSBanksNRoyMA, et al.A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatr; 58: 23-29. DOI: 10.1177/088740341305805s04.
23.
DasAKMalikAHaddadPM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol2014; 4: 179–185.
24.
PotkinSBeraRZubekD, et al.Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry2013; 13: 261.
25.
GroverSSahooSBnS, et al.Attitude and perceptions of patients towards long acting depot injections (LAIs). Asian J Psychiatr2019; 44: 200–208.
26.
SemrauMEvans-LackoSKoschorkeM, et al.Stigma and discrimination related to mental illness in low- and middle-income countries. Epidemiol Psychiatr Sci2014; 24: 382–394.
27.
WehringHJThedfordSKoolaM, et al.Patient and health care provider perspectives on long acting injectable antipsychotics in schizophrenia and the introduction of olanzapine long-acting injection. J Cent Nerv Syst Dis2011; 3: JCNSD.S4091.
28.
WeidenPJRomaRSVelliganDI, et al.The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry2015; 76: 684–690.
29.
AchtyesESimmonsASkabeevA, et al.Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry2018; 18(1): 292.
30.
HigashiKMedicGLittlewoodKJ, et al.Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol2013; 3(4): 200–218.
